283 results on '"Patt, Y."'
Search Results
2. POS0504 INCREASED RISK FOR PULMONARY EMBOLISM AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS – RESULTS FROM A LARGE DATABASE ANALYSIS
3. POS0868 MORTALITY RISK ANALYSIS IN SARCOIDOSIS: A LARGE SCALE POPULATION BASED COHORT STUDY
4. POS1252 ANTI-RO AND ANTI-LA SEROPOSITIVITY IS ASSOCIATED WITH INCREASED RATES OF ISCHEMIC HEART DISEASE IN ADULTS- RESULTS FROM A LARGE POPULATION-BASED STUDY
5. Deep Learning in Coeliac Disease: A Systematic Review on Novel Diagnostic approaches to disease diagnosis
6. 10349 Pregnancy Outcomes Following Abdominal Laparoscopic Surgeries during Pregnancy
7. POS0391 INCREASED RISK OF OSTEOPOROSIS AND HEAD OF FEMUR FRACTURES IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER - A LARGE RETROSPECTIVE COHORT STUDY
8. POS0658 ANKYLOSING SPONDYLITIS IS ASSOCIATED WITH INCREASED PREVALENCE OF VALVULAR HEART DISEASES: A POPULATION BASED STUDY
9. POS0972 INCREASED RISK FOR STROKE IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER, RESULTS FROM A LARGE POPULATION-BASED STUDY
10. POS1213 RISK OF ATHEROSCLEROSIS-RELATED DISEASES IN ADULTS WITH POLYMYOSITIS AND DERMATOMYOSITIS: A LARGE SCALE POPULATION-BASED STUDY
11. Regionale Therapie hepatischer Tumoren
12. Regionale Therapie hepatischer Tumoren
13. APPROPRIATENESS of TREATMENT STRATEGIES for COLORECTAL LIVER METASTASES (CLM): A DECISION MODEL BASED on CONSENSUS DETECTION WITHIN AN INTERNATIONAL EXPERT PANEL: 13
14. 99Tcm-IMMU4 imaging in recurrent colorectal cancer: Efficacy and impact on surgical management
15. 18. CEA-SCAN™ can be used to predict resectability of recurrent colorectal cancer
16. SysRT: A modular multiprocessor RTOS simulator for early design space exploration
17. Regional-Arterial Chemotherapy or Arterial Embolization in the Management of Various Stages of Colon Cancer
18. Run-time Mapping Algorithm for Dynamic Workloads using Process Merging Transformations
19. INCREASED RISK OF OSTEOPOROSIS AND HEAD OF FEMUR FRACTURES IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER - A LARGE RETROSPECTIVE COHORT STUDY.
20. P-325 A Phase II trial using a combination of Oxaliplatin, Capecitabine, and Celecoxib with concurrent radiation for newly diagnosed resectable rectal cancer: COX2 expression in relationship to outcomes
21. Arterial Therapy in the Management of Resectable and Nonresectable Metastatic Colorectal Cancer in the Liver
22. MDAH Surgical Experience with Implantable Infusaid® Pumps and Medtronic Drug Administration Devices®
23. RISK OF ATHEROSCLEROSIS-RELATED DISEASES IN ADULTS WITH POLYMYOSITIS AND DERMATOMYOSITIS: A LARGE SCALE POPULATION-BASED STUDY.
24. INCREASED RISK FOR STROKE IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER, RESULTS FROM A LARGE POPULATION-BASED STUDY.
25. ANKYLOSING SPONDYLITIS IS ASSOCIATED WITH INCREASED PREVALENCE OF VALVULAR HEART DISEASES: A POPULATION BASED STUDY.
26. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.
27. Phase II trial using combination of oxaliplatin, capecitabine, and celecoxib with concurrent radiation in patients with operable rectal cancer.
28. Phase II trial of gemcitabine (G), oxaliplatin (O), and erlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancers (BTC).
29. Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis
30. A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity
31. TRENDS IN HEPATOCELLULAR CARCINOMA IN NEW MEXICO, 1973-2002.
32. Foreword
33. Demographics from the ETHECC (Evaluation of THYMITAQ [nolatrexed dihydrochloride] in Hepatocellular Carcinoma [HCC]) trial population
34. Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial
35. Cost-minimization comparison of infusion based FOLFIRI (5-fluorouracil and leucovorin) versus oral based XELIRI (capecitabine and irinotecan) in metastatic colorectal cancer (mCRC)
36. Requirements, bottlenecks, and good fortune: agents for microprocessor evolution
37. Phase II Trial of Intravenous CI-980 (NSC 370147) in Patients with Metastatic Colorectal Carcinoma
38. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
39. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas.
40. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
41. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group.
42. A phase I evaluation of chronotropic delivery of floxuridine by hepatic arterial infusion in patients with metastatic colorectal cancer
43. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
44. CLINICAL UTILITY OF IMAGING WITH 99=TC-LABELED IMMU-4 Fab' FRAGMENT IN PATIENTS(pts) WITH CANCER OF THE COLON OR RECTUM
45. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival.
46. Phase II trial of docetaxel (Taxotere®) in metastatic colorectal carcinoma
47. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels.
48. Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues.
49. Arterial complications from long-term hepatic artery chemoinfusion catheters: evaluation with CT.
50. CLINICAL EFFICACY OF 99mTc LABELED Fab1 FRAGMENT OF THE ANTICEA ANTIBODY IN PATIENTS WITH COLON CARCINOMA AND A RISING SERUM CEA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.